Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 23Pituitary Neoplasms 10Pheochromocytoma 10Carcinoma, Neuroendocrine 9Thyroid Neoplasms 8Sarcoma 8Thyroid Cancer, Papillary 6Paraganglioma 5Ovarian Neoplasms 5Neuroblastoma 5Adrenocortical Carcinoma 5Small Cell Lung Carcinoma 4Parathyroid Neoplasms 4Pancreatic Neoplasms 4Osteosarcoma 4Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 4Adrenal Gland Neoplasms 4Thyroid Carcinoma, Anaplastic 3Stomach Neoplasms 3Pituitary ACTH Hypersecretion 3Melanoma 3Head and Neck Neoplasms 3Cushing Syndrome 3Colorectal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Carcinoma 3

Interventions

Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastroenteropancreatic Neuroendocrine Tumor × Endocrine × 30 days × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡